Finance

Lists
Outlook: 87.0% bullish·4.3% bearish
Go to analysis
RZLT:NASDAQ
Rezolute Inc
$4.38
+1.39%
(+0.060) 1D
$4.38
0.00% (0.00)
After hours
Closed: Oct 7, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RZLT...
Open
$4.29
High
$4.56
Low
$4.23
Mkt. cap
423.64M
Avg. vol.
1.57M
Volume
1.69M
52-wk high
$11.46
52-wk low
$1.07
EPS
-$0.75
Beta
0.54
Shares outstanding
96.72M
No. of employees
58
Open
$4.29
High
$4.56
Low
$4.23
Mkt. cap
423.64M
Avg. vol.
1.57M
Volume
1.69M
52-wk high
$11.46
52-wk low
$1.07
EPS
-$0.75
Beta
0.54
Shares outstanding
96.72M
No. of employees
58
News stories
From web sources and news partners
About Rezolute Inc
CEO-
Employees58
Founded2010
HeadquartersRedwood City, California, United States
SectorBiotechnology
Websiterezolutebio.com
Analyst ratings
Based on 7 analysts giving stock ratings to RZLT in the past 3 months
Strong buy
Buy
7
Hold
0
Sell
0
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for RZLT in the last 3 months.
Highest
Current $4.38
$15.00 (+242.47%)
Average
$9.33 (+113.01%)
Lowest
$6.00 (+36.99%)
Analyst
Recommendation
Action
Price target
Projected
Date
Daniel Brims
Lake Street
Buy
Reiterated
$12.00
+174%
10/06/2026
Julian Harrison
BTIG
Buy
Reiterated
$6.00
+37%
10/05/2026
Jason Butler
Citizens JMP
Buy
Maintained
$15.00
+242.5%
10/06/2026
Pete Stavropoulos
Cantor Fitzgerald
Buy
Upgraded
-
-
10/05/2026
Yun Zhong
Wedbush
Buy
Maintained
$6.00
+37%
10/05/2026
Douglas Tsao
H.C. Wainwright
Buy
Maintained
$10.00
+128.3%
10/05/2026
Albert Lowe
Craig-Hallum
Buy
Upgraded
$7.00
+59.8%
09/29/2026
Debjit Chattopadhyay
Guggenheim
Buy
Reiterated
$11.00
+151.1%
06/15/2026
Jason McCarthy
Maxim Group
Buy
Reiterated
$14.00
+219.6%
06/03/2026
Matt Hewitt
Craig-Hallum
Hold
Maintained
-
-
06/02/2026
Catherine Novack
JonesTrading
Buy
Reiterated
$6.00
+37%
06/02/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
13.03M
13.33M
10.39M
14.76M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
6.79M
9.39M
5.48M
6.80M
Operating expense
19.82M
22.72M
15.87M
21.56M
Total operating expenses
19.82M
22.72M
15.87M
21.56M
Operating income
-19.82M
-22.72M
-15.87M
-21.56M
Other non operating income
-15.00K
-
-
15.00K
EBT including unusual items
-18.15M
-22.77M
-16.17M
-20.49M
EBT excluding unusual items
-18.15M
-21.27M
-14.67M
-20.49M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-18.15M
-22.77M
-16.17M
-20.49M
Net profit margin
-
-
-
-
Earnings per share
-0.18
-0.22
-0.16
-0.20
Interest and investment income
1.68M
1.45M
1.20M
1.06M
Interest expense
-
-
-
-
Net interest expenses
1.68M
1.45M
1.20M
1.06M
Depreciation and amortization charges
-
-
-
-
EBITDA
-19.81M
-22.71M
-15.86M
-21.55M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps